Education
About Us
Working with TipRanks
Follow Us
Greenwich LifeSciences (GLSI)
NASDAQ:GLSI
Total Valuation
Greenwich LifeSciences has a market cap or net worth of $156.00M. The enterprise value is ―.
Market Cap$156.00M
Enterprise Value―
Share Statistics
Greenwich LifeSciences has 13,630,257 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,630,257
Owned by Insiders53.23%
Owned by Institutions0.02%
Financial Efficiency
Greenwich LifeSciences’s return on equity (ROE) is -6.23 and return on invested capital (ROIC) is -631.87%.
Return on Equity (ROE)-6.23
Return on Assets (ROA)-3.86
Return on Invested Capital (ROIC)-631.87%
Return on Capital Employed (ROCE)-6.32
Revenue Per Employee0.00
Profits Per Employee-3.95M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Greenwich LifeSciences is ―. Greenwich LifeSciences’s PEG ratio is -0.12.
PE Ratio―
PS Ratio0.00
PB Ratio57.68
Price to Fair Value57.68
Price to FCF-20.11
Price to Operating Cash Flow-16.75
PEG Ratio-0.12
Income Statement
In the last 12 months, Greenwich LifeSciences had revenue of 0.00 and earned -15.79M in profits. Earnings per share was -1.21.
Revenue0.00
Gross Profit-3.61K
Operating Income-16.01M
Pretax Income-15.79M
Net Income-15.79M
EBITDA-15.79M
Earnings Per Share (EPS)-1.21
Cash Flow
In the last 12 months, operating cash flow was -8.50M and capital expenditures 3.00, giving a free cash flow of -8.50M billion.
Operating Cash Flow-8.50M
Free Cash Flow-8.50M
Free Cash Flow per Share-0.62
Dividends & Yields
Greenwich LifeSciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.45
52-Week Price Change-22.43%
50-Day Moving Average11.40
200-Day Moving Average10.98
Relative Strength Index (RSI)44.82
Average Volume (3m)75.95K
Important Dates
Greenwich LifeSciences upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Greenwich LifeSciences as a current ratio of 2.62, with Debt / Equity ratio of 0.00%
Current Ratio2.62
Quick Ratio2.62
Debt to Market Cap0.00
Net Debt to EBITDA0.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Greenwich LifeSciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Greenwich LifeSciences EV to EBITDA ratio is -9.00, with an EV/FCF ratio of -19.55.
EV to Sales0.00
EV to EBITDA-9.00
EV to Free Cash Flow-19.55
EV to Operating Cash Flow-19.55
Balance Sheet
Greenwich LifeSciences has $3.13M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.13M billion.
Cash & Marketable Securities$3.13M
Total Debt$0.00
Net Cash$3.13M
Net Cash Per Share$0.23
Tangible Book Value Per Share$0.19
Margins
Gross margin is -24.25%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-24.25%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Greenwich LifeSciences is $45.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$45.00
Price Target Upside302.50% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―